Cargando…

Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study

Background: To assess the role of nodal involvement in stage III renal cell carcinoma (RCC) according to the American Joint Committee on Cancer (AJCC) 8th staging system. We compared the survival outcomes of RCC patients with pT(1−3)N(1)M(0) disease and those with pT(3)N(0)M(0) or stage IV (stratifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jianglong, Li, Qin, Li, Ping, Wang, Shijie, Zhang, Rui, Qiao, Yunfeng, Song, Qibin, Fu, Zhenming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096477/
https://www.ncbi.nlm.nih.gov/pubmed/32266145
http://dx.doi.org/10.3389/fonc.2020.00365
_version_ 1783510812791406592
author Han, Jianglong
Li, Qin
Li, Ping
Wang, Shijie
Zhang, Rui
Qiao, Yunfeng
Song, Qibin
Fu, Zhenming
author_facet Han, Jianglong
Li, Qin
Li, Ping
Wang, Shijie
Zhang, Rui
Qiao, Yunfeng
Song, Qibin
Fu, Zhenming
author_sort Han, Jianglong
collection PubMed
description Background: To assess the role of nodal involvement in stage III renal cell carcinoma (RCC) according to the American Joint Committee on Cancer (AJCC) 8th staging system. We compared the survival outcomes of RCC patients with pT(1−3)N(1)M(0) disease and those with pT(3)N(0)M(0) or stage IV (stratified as pT(4)N(any)M(0) and pT(any)N(any)M(1)) disease in a large population-based cohort. Methods: A cohort of 3,112 eligible patients with RCC was identified from the Surveillance, Epidemiology, and End Results (SEER) database, registered between January 2004 and December 2015. Kaplan-Meier and Cox proportional hazards models were used to evaluate the overall survival (OS), and cancer-specific survival (CSS). The prognostic value of the modified stage for pT(1−3)N(1)M(0) disease was assessed by nomogram-based analyses. Propensity score matching (PSM) was used to adjust for potential baseline confounding. Results: Patients with pT(1−3)N(1)M(0) disease showed similar survival outcomes (median OS 41.0 vs. 38.0 months, P = 0.77; CSS 45.0 vs. 39.0 months, P = 0.59) to pT(4)N(any)M(0) patients, whereas the significantly better survival outcome was found for pT(3)N(0)M(0) patients. After PSM, comparable survival rates were observed between pT(1−3)N(1)M(0) group and pT(4)N(any)M(0) group, which were still significantly worse than the survival of pT(3)N(0)M(0) patients. The modified stage IIIA (pT(3)N(0)M(0)), IIIB (pT(1−3)N(1)M(0), pT(4)N(any)M(0)), and IV (pT(any)N(any)M(1)) showed higher predictive accuracy than AJCC stage system in the nomogram-based analyses (concordance index: 0.70 vs. 0.68, P < 0.001 for OS; 0.71 vs. 0.69, P < 0.001 for CSS). Conclusions: The pT(1−3)N(1)M(0) RCC might be reclassified as stage IIIB together with pT(4)N(any)M(0) disease for better prediction of prognosis, further examination and validation are warranted.
format Online
Article
Text
id pubmed-7096477
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70964772020-04-07 Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study Han, Jianglong Li, Qin Li, Ping Wang, Shijie Zhang, Rui Qiao, Yunfeng Song, Qibin Fu, Zhenming Front Oncol Oncology Background: To assess the role of nodal involvement in stage III renal cell carcinoma (RCC) according to the American Joint Committee on Cancer (AJCC) 8th staging system. We compared the survival outcomes of RCC patients with pT(1−3)N(1)M(0) disease and those with pT(3)N(0)M(0) or stage IV (stratified as pT(4)N(any)M(0) and pT(any)N(any)M(1)) disease in a large population-based cohort. Methods: A cohort of 3,112 eligible patients with RCC was identified from the Surveillance, Epidemiology, and End Results (SEER) database, registered between January 2004 and December 2015. Kaplan-Meier and Cox proportional hazards models were used to evaluate the overall survival (OS), and cancer-specific survival (CSS). The prognostic value of the modified stage for pT(1−3)N(1)M(0) disease was assessed by nomogram-based analyses. Propensity score matching (PSM) was used to adjust for potential baseline confounding. Results: Patients with pT(1−3)N(1)M(0) disease showed similar survival outcomes (median OS 41.0 vs. 38.0 months, P = 0.77; CSS 45.0 vs. 39.0 months, P = 0.59) to pT(4)N(any)M(0) patients, whereas the significantly better survival outcome was found for pT(3)N(0)M(0) patients. After PSM, comparable survival rates were observed between pT(1−3)N(1)M(0) group and pT(4)N(any)M(0) group, which were still significantly worse than the survival of pT(3)N(0)M(0) patients. The modified stage IIIA (pT(3)N(0)M(0)), IIIB (pT(1−3)N(1)M(0), pT(4)N(any)M(0)), and IV (pT(any)N(any)M(1)) showed higher predictive accuracy than AJCC stage system in the nomogram-based analyses (concordance index: 0.70 vs. 0.68, P < 0.001 for OS; 0.71 vs. 0.69, P < 0.001 for CSS). Conclusions: The pT(1−3)N(1)M(0) RCC might be reclassified as stage IIIB together with pT(4)N(any)M(0) disease for better prediction of prognosis, further examination and validation are warranted. Frontiers Media S.A. 2020-03-19 /pmc/articles/PMC7096477/ /pubmed/32266145 http://dx.doi.org/10.3389/fonc.2020.00365 Text en Copyright © 2020 Han, Li, Li, Wang, Zhang, Qiao, Song and Fu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Han, Jianglong
Li, Qin
Li, Ping
Wang, Shijie
Zhang, Rui
Qiao, Yunfeng
Song, Qibin
Fu, Zhenming
Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study
title Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study
title_full Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study
title_fullStr Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study
title_full_unstemmed Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study
title_short Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study
title_sort reassessment of american joint committee on cancer staging for stage iii renal cell carcinoma with nodal involvement: propensity score matched analyses of a large population-based study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096477/
https://www.ncbi.nlm.nih.gov/pubmed/32266145
http://dx.doi.org/10.3389/fonc.2020.00365
work_keys_str_mv AT hanjianglong reassessmentofamericanjointcommitteeoncancerstagingforstageiiirenalcellcarcinomawithnodalinvolvementpropensityscorematchedanalysesofalargepopulationbasedstudy
AT liqin reassessmentofamericanjointcommitteeoncancerstagingforstageiiirenalcellcarcinomawithnodalinvolvementpropensityscorematchedanalysesofalargepopulationbasedstudy
AT liping reassessmentofamericanjointcommitteeoncancerstagingforstageiiirenalcellcarcinomawithnodalinvolvementpropensityscorematchedanalysesofalargepopulationbasedstudy
AT wangshijie reassessmentofamericanjointcommitteeoncancerstagingforstageiiirenalcellcarcinomawithnodalinvolvementpropensityscorematchedanalysesofalargepopulationbasedstudy
AT zhangrui reassessmentofamericanjointcommitteeoncancerstagingforstageiiirenalcellcarcinomawithnodalinvolvementpropensityscorematchedanalysesofalargepopulationbasedstudy
AT qiaoyunfeng reassessmentofamericanjointcommitteeoncancerstagingforstageiiirenalcellcarcinomawithnodalinvolvementpropensityscorematchedanalysesofalargepopulationbasedstudy
AT songqibin reassessmentofamericanjointcommitteeoncancerstagingforstageiiirenalcellcarcinomawithnodalinvolvementpropensityscorematchedanalysesofalargepopulationbasedstudy
AT fuzhenming reassessmentofamericanjointcommitteeoncancerstagingforstageiiirenalcellcarcinomawithnodalinvolvementpropensityscorematchedanalysesofalargepopulationbasedstudy